Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 11,601–11,700 of 15,747
Carro, B. (2021) · doi:10.31219/osf.io/v6zym · Cited by 2
Vinh, D., Gouin, J., Cruz-Santiago, D., Canac-Marquis, M., Bernier, S., Bobeuf, F., Sengupta, A., Brassard, J., Guerra, A., Dziarmaga, R., et al. (2021) · medRxiv · doi:10.1101/2021.09.16.21263704 · Cited by 3
The shape of waning vaccinal immunity: Implications for control
Northrup, G. R., Boots, M., & Saad-Roy, C. M. (2025) · PLOS complex systems. · doi:10.1371/journal.pcsy.0000071 · Cited by 3
“The watershed moment during the COVID-19 pandemic was the development and deployment of safe vaccines [7–9] and while current formulations of COVID-19 vaccines only transiently prevent infection, effective transmission-blocking vaccines can result in pathogen control (see e.g. [10–12]).”
Mitsumura, T., Okamoto, T., Tosaka, M., Yamana, T., Shimada, S., Iijima, Y., Sakakibara, R., Shibata, S., Honda, T., Shirai, T., et al. (2022) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2022.080 · Cited by 2
Mai, F., Bergmann, W., Reisinger, E. C., & Müller‐Hilke, B. (2024) · Journal of Virology · doi:10.1128/jvi.01912-23 · Cited by 2
COVID-19 mRNA or viral vector vaccine type and subject sex influence the SARS-CoV-2 T-cell response
Tong, S., Litwin, S. M., Epel, E. S., Lin, J., Drury, S. S., Hecht, F. M., Robinson, J. E., Prather, A. A., & Norton, E. B. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127420 · Cited by 2
Mericliler, M. (2023) · Cureus · doi:10.7759/cureus.41460 · Cited by 2
“Messenger RNA (mRNA) vaccines for COVID-19 have proven to be highly effective in randomized trials, substantially reducing the risk of COVID-19, especially severe disease, and have been the most widely administered vaccines against COVID-19 [1,2].”
BackgroundThe Natural History of SARS-CoV-2-Incurred Disease: From Infection to Long COVID
Liang, K., Teng, Y., Liao, Y.-T., Yarmishyn, A. A., Chiang, S., Hung, W.-C., Hsiao, C.-Y., Tsai, E.-T., Chang, T.-J., Yang, D., et al. (2024) · International Journal of Translational Medicine · doi:10.3390/ijtm4010004 · Cited by 5
“In the meantime, mass vaccination against COVID-19 has been effective in adults [12,13], children, and adolescents [14].”
BackgroundLee, W., & Kurien, P. A. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113410 · Cited by 2
Urticárias crônicas induzidas: atualização do tema
Dortas, S. D., Azizi, G. G., Sousa, A. C. M., et al. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200047 · Cited by 2
A novel mAb broadly neutralizes SARS‐CoV‐2 VOCs in vitro and in vivo, including the Omicron variants
Kan, Q., Lin, X. Z., Li, T., Ke, X., Jian, X., Hou, L., Zhang, W., Wan, Z., Xie, Q., Shao, H., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28657 · Cited by 2
Telomerase modRNA Offers a Novel RNA ‐Based Approach to Treat Human Pulmonary Fibrosis
Ye, J. L., Grieger, K. M., Lu, D., Brandenberger, C., Juchem, M., Jordan, M., Oehlsen, L., Zardo, P., Werlein, C., Hesse, C., et al. (2025) · Aging Cell · doi:10.1111/acel.70240 · Cited by 4
Mushtaq, S., Khan, M. K., Khan, M. Q. A., Rathore, M. A., Parveen, B., Noor, M., Ghani, E., Tahir, A. B., Tipu, H. N., & Lin, B. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01005-4 · Cited by 6
Mason, K. A., Wurtz, H. M., Boracci, S., & Willen, S. S. (2024) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2024.100454 · Cited by 1
Agarwal, A., Baghmar, S., Qureshi, S. R., Khurana, A., Setia, R., Khan, M. A., Barman, P., Kapoor, R. K., Hasthavaram, N. R., Kumar, R., et al. (2021) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0041-1733823 · Cited by 2
Nanomaterials-enabled mRNA delivery for Cancer immunotherapy
Chen, Y., Liang, S., Peng, Y., Ma, K., Yun, K., Ma, X., Hai, L., Mei, L., Wang, L., & Wang, Z. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216945 · Cited by 2
Beltz, L. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98809-4.00013-9 · Cited by 2
The ethics of clinical research in the era of COVID-19
Vitti, J. N., Vitti, R., Chu, K., & Mellis, S. J. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1359654 · Cited by 6
Reducing COVID-19 Vaccine Hesitancy From a Decisional Conflict Model: A Cross-Sectional Study
Hiroyama, N., Okubo, N., Takahashi, N., & Misumi, J. (2023) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580231162524 · Cited by 3
Singh, M. K., Jain, M., Shyam, H., Sahu, D. K., Mishra, A., Shankar, P., Kumar, S., & Singh, V. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07308-1 · Cited by 2
“Whereas, apart from the above-cited vaccine, BNT162b2 is mRNA based drug with 95% effectiveness against the Covid-19 in clinical trials (NCT04368728) [76].”
BackgroundHealth research versus the virus: strengthening systems, saving lives
Hanney, S. R., & Yazdizadeh, B. (2025) · Health Research Policy and Systems · doi:10.1186/s12961-025-01354-4 · Cited by 4
“…and The New England Journal of Medicine about mRNA vaccines trialled mostly in the United States, but also Germany, from both BioN-Tech/Pfizer [66, 67] and Moderna [68–71], and in Nature and The Lancet about the Oxford/AstraZeneca vaccine (with trial sites in the United Kingdom and also in Brazil…”
Seven-month persistence of COVID-19 vaccine-induced lymphadenopathy: a case report
Hwang, M., Dua, H., Mulligan, A. M., et al. (2025) · Journal of Medical Case Reports · doi:10.1186/s13256-025-05188-0 · Cited by 2
“In the initial randomized trial of the Pfizer COVID-19 vaccine, 0.3% of vaccinated individuals reported the development of lymphadenopathy [3].”
InfluentialLarsen, V. B., Gunnes, N., Gran, J. M., Dahl, J., Bøås, H., Watle, S. V., Berild, J. D., Greve‐Isdahl, M., Størdal, K., Gulseth, H. L., et al. (2023) · medRxiv · doi:10.1101/2023.12.13.23299926 · Cited by 2
Justiz-Vaillant, A. A., Roopnarine, K., Solomon, S., Phillips, A., Salandy, S., Subero, A., Seepersad, S., Span, N., Ramnath, P., Ramnarine, A., et al. (2025) · Microorganisms · doi:10.3390/microorganisms13010135 · Cited by 4
de León, U. A.-P., Pérez, Á. G. C., & Avila-Vales, E. J. (2023) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2023484 · Cited by 2
Suitability of Polymyxin B as a Mucosal Adjuvant for Intranasal Influenza and COVID-19 Vaccines
Yoshino, N., Yokoyama, T., Sakai, H., et al. (2023) · Vaccines · doi:10.3390/vaccines11111727 · Cited by 2
Garrett, M., Galloway, J. G., Wolf, C., et al. (2021) · bioRxiv · doi:10.1101/2021.10.05.463210 · Cited by 4
Shehab, M., Alrashed, F., Alfadhli, A., Alsayegh, A., AlDallal, U., Alsayegh, M., Cherian, P., Alkhair, I., Thanaraj, T. A., Channanath, A. M., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.933996 · Cited by 2
“In addition, a previous study demonstrated that the immunogenicity of COVID-19 vaccines varies according to the immunosuppressive drug exposure and is attenuated in recipients of infliximab, infliximab plus thiopurines, and tofacitinib (15).”
BackgroundInfluentialZheng, Z., Wu, H., Sun, X., Lu, Y., Song, Y., Luo, Y., Zhou, T., Feng, M., Wan, P., Zhu, J., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29543 · Cited by 2
Lung damage in SARS ‐ CoV ‐2 patients: An autopsy study in the era of vaccination
Bussani, R., Porcari, A., Pinamonti, M., Iacobucci, A., Belladonna, E., Tomasini, A., Zanconati, F., Collesi, C., Giacca, M., Berlot, G., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14325 · Cited by 3
Paranilam, J., Arcioni, F., Franco, A., Lai, K. Z. H., Brown, J. A., & Kimball-Carroll, S. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01051-9 · Cited by 1
“Vaccine efficacy against symptomatic infection, severe disease, hospitalization, or death has been widely proven in the immunocompetent popu‑ lation [13–22].”
BackgroundHadar, E., Dollinger, S., & Wiznitzer, A. (2021) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2021.1937110 · Cited by 3
Brisotto, G., Montico, M., Turetta, M., Zanussi, S., Cozzi, M. R., Vettori, R., Boschin, R. B., Vinante, L., Matrone, F., Revelant, A., et al. (2023) · Viruses · doi:10.3390/v15061276 · Cited by 2
“The onset of post-vaccination side effects with SARS-CoV-2 mRNA vaccines was commonly reported, particularly after the second dose [17,18,34,35].”
Corticosteroids and mRNA Vaccines: A Word of Caution
Zhong, Z., Combes, F., & Sanders, N. N. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.029 · Cited by 4
Konrath, K. M., Liaw, K., Wu, Y.-H., Zhu, X.-Z., Walker, S. N., Xu, Z., Schultheis, K., Chokkalingam, N., Du, J., Tursi, N. J., et al. (2021) · bioRxiv · doi:10.1101/2021.04.28.441474 · Cited by 1
“Most 221 SARS-CoV-2 vaccines require at least two doses[63, 64].”
Šín, R., Lochmannová, A., Green, G., & Kubiska, M. (2026) · European Geriatric Medicine · doi:10.1007/s41999-026-01477-z · Cited by 2
“Large COVID-19 vaccine cohorts show that reactogenicity varies by age, sex, vaccine type, and prior SARS-CoV-2 infection [26–29], with younger adults and women generally reporting more local and systemic symptoms than older men [30, 31].”
da Silva, J. V. G. O., & Santos, E. D. O. (2026) · Archives of Microbiology · doi:10.1007/s00203-025-04706-4 · Cited by 3
“…vaccine based on adenovirus and mRNA-based vaccines (Pfizer–BioNTech and Moderna) approved for emergency use in the COVID-19 pandemic (Baden 2021; Polack 2020 ); (iii) cold plasma as an efficient solution for virus inactivation has been applied to viruses such as noro-virus, adenovirus,…”
Immunogenicity of the Two mRNA SARS-CoV-2 Vaccines in a Large Cohort of Dialysis Patients
Tsoutsoura, P., Xagas, E., Kolovou, K., et al. (2022) · Infectious Disease Reports · doi:10.3390/idr14060093 · Cited by 2
Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers
Spitaleri, G., Aliaga, P. T., Catania, C., Signore, E. D., Attili, I., Santoro, C., Giugliano, F., Giachetti, P. P. M. B., Curigliano, G., Passaro, A., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.10.004 · Cited by 2
“At the time of writing, the Italian Medicine Agency (AIFA) has authorized the use of five vaccines in Italy: two nucleoside-modified RNA vaccine (BNT162b2 vaccine, BioNTech/Pfizer; mRNA-1273 vaccine, Moderna)[16][17], two chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19 vaccine, NIHR Oxford Biomedical Research…”
BackgroundInfluentialWeigl, J. A. I., Werlang, T., Wessendorf, M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-484166/v1 · Cited by 2
Wang, L., Zhuang, L., Li, T., Hara, H., Cooper, D. K. C., Leng, J., Pan, D., Zheng, S., Wang, Y., Xu, X. X., et al. (2025) · Xenotransplantation · doi:10.1111/xen.70050 · Cited by 2
“These vaccines include traditional inactivated virus formulations [20, 21] and mRNA-based vaccines [22, 23].”
Self-citationBafleh, W. S., Abdulsamad, H. M. R., Al-Qaraghuli, S. M., Khatib, R. Y. E., Elbahrawi, R. T., Abdukadir, A. M., Alsawae, S. M., Dimassi, Z., Hamdan, H., & Kashir, J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1198848 · Cited by 2
“However, while such technology is associated with certain advantages, such new mRNA technology also exhibit significant drawbacks such as mRNA efficiency, safety, stability, immunogenicity, and enhancement of delivery systems (Table 2; (Almalki et al., 2021; Liu et al., 2021; Pardi et al., 2018; Polack et al., 2020; S…”
BackgroundAli, H., Naz, S., & Bhutto, N. A. (2026) · Journal of Cleaner Production · doi:10.1016/j.jclepro.2026.147979 · Cited by 2
Impact of Memory T Cells on SARS-COV-2 Vaccine Response in Hematopoietic Stem Cell Transplant
(2023) · doi:10.1101/2023.10.26.564259 · Cited by 2
“SARS-CoV-2 mRNA vaccines, including Pfizer’s BNT162b2 and Moderna’s mRNA-1273, were made available under Emergency Use Authorization (EUA) in December 2020 after they showed a 95% and 94.1% efficacy, respectively, in preventing severe symptomatic COVID-19 infection (6, 7).”
MethodInfluentialImmunomodulatory Delivery Materials for Tissue Repair
Est-Witte, S. E., Jain, M., Ben‐Akiva, E., Yang, J., Warren, T., Tzeng, S. Y., & Green, J. J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501400 · Cited by 4
Adibi, A., Mozafarihashjin, M., & Sadatsafavi, M. (2021) · medRxiv · doi:10.1101/2021.04.11.21255138 · Cited by 2
“From a vaccine efficacy point of view, determining the superiority of one vaccine to the other is not straightforward; there is more to the apparent but variable 5%-33% efficacy gap (symptomatic COVID-19; 7-14 days after second dose) between mRNA and AZ COVID-19 vaccines [Polack et al. (2020); Baden et al. (2021); Ast…”
BackgroundInfluentialPreparing for COVID-19 Vaccination: Guidelines for Healthcare Personnel
Kim, Y. R., Kim, D. J., & Choi, Y. H. (2021) · Korean Journal of Healthcare-Associated Infection Control and Prevention · doi:10.14192/kjicp.2021.26.1.3 · Cited by 2
COVID-19 Vaccine Effectiveness in Oncology Patients
Costa, R. L. (2022) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2022.13.4.6 · Cited by 2
Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Bideau, M. L., Edouard, S., Colson, P., Chahinian, H., Raoult, D., Yahi, N., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-783298/v1 · Cited by 2
Hasan, A., Arefanian, H., Channanath, A. M., Al‐Khairi, I., Cherian, P., Devarajan, S., Thanaraj, T. A., Abu‐Farha, M., Abubaker, J. A., & Al‐Mulla, F. (2022) · Vaccines · doi:10.3390/vaccines10081226 · Cited by 2
“demonstrated effectiveness in preventing severe COVID-19 [11,12].”
Houseini, S. T., Mahmanzar, M., Rahimian, K., Bayat, S., Gholamzad, A., Sisakht, M. M., Farhadi, A., Kuehu, D. L., & Deng, Y. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70586 · Cited by 2
“For instance, the Delta variant reduces the efficacy of therapies more than the other variants [16].”
Hajduczki, A., Chang, W. C., Barrera, R. A. D. L., Wood, J. F., Chen, W.-H., Martinez, E. J., Jensen, J. L., Sankhala, R. S., Smith, C., Anderson, A., et al. (2025) · Vaccines · doi:10.3390/vaccines13101041 · Cited by 2
Elfessi, Z. Z., & Rubinstein, I. (2022) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0834 · Cited by 2
Garg, R., Hussain, M., & Friedrich, M. G. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1186556 · Cited by 2
Hospital-based RNA TherapeuticsPreprint
Damase, T. R., Sukhovershin, R. A., Zhang, M., et al. (2022) · Preprints.org · doi:10.20944/preprints202201.0073.v1 · Cited by 2
“Consequently, Pfizer and Moderna replaced 100% of the uridine residues in their COVID-19 mRNA vaccines (Pfizer/BioNTech (BNT162b2) and Moderna`s mRNA-1273) with m1Ψ to improve the performance of their vaccines(Jackson et al. 2020; Polack et al. 2020; Corbett et al. 2021).”
BackgroundInfluentialIn Silico Design of a Trans‐Amplifying RNA‐Based Vaccine against SARS‐CoV‐2 Structural Proteins
Nafian, F., Soleymani, G., Pourmanouchehri, Z., Kiyanjam, M., Nafian, S., Mohammadi, S. M., Jeyroudi, H., Jalaei, S. B., & Sabzpoushan, F. (2024) · Advances in Virology · doi:10.1155/2024/3418062 · Cited by 3
Acute hepatitis following mRNA BNT162b2 COVID-19 vaccination
Cheah, M., Girgis, S., & Bain, V. G. (2022) · Canadian Liver Journal · doi:10.3138/canlivj-2022-0014 · Cited by 2
Teófilo, V. S. G., Pinho, P. R. A., Cordeiro, G., Saldanha, N., Matos, P. M. M., Ribeiro, R. A. M., Moreira, S., Miller, M. S. F., Dias, A. M., Couto, M. F. R., et al. (2023) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000219 · Cited by 2
Vagts, C. L., Sweis, J. J. G., Sweis, N. W. G., Ascoli, C., Rottoli, P., Martone, F. M., Wells, A. U., Judson, M. A., Sweiss, N., Lower, E. E., et al. (2023) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v40i2.14388 · Cited by 3
“Our findings, though retrospective and subject to recall bias, demonstrate that vaccination against COVID-19 was generally well tolerated in subjects with sarcoidosis with mild side effects in a minority of patients comparable to what is experienced by the general population (27-30).”
Batchi-Bouyou, A. L., Djontu, J. C., Ingoba, L. L., Mougany, J. S., Mouzinga, F. H., Ntabi, J. D. M., Kouikani, F. Y., Ndala, A. C. M., Diafouka-Kietela, S., Ampa, R., et al. (2024) · BMC Immunology · doi:10.1186/s12865-024-00625-z · Cited by 2
Antibody titers decline 3-month post-vaccination with BNT612b2Preprint
Favresse, J., Bayart, J., Mullier, F., Elsen, M., Eucher, C., Eechhoudt, S. V., Roy, T., Wieërs, G., Laurent, C., Dogné, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-574216/v1 · Cited by 2
“The efficacy and safety of the two-dose regimen of BNT162b2 mRNA COVID-19 vaccine (PfizerBioNTech, Mainz, Germany) has been proved and led to its approval by several regulatory authorities in late December 2020.(1) Several studies have reported on the humoral response in vaccinated subjects but the results were only a…”
BackgroundPost-vaccination SARS-cov-2 infection in nursing home residents, Bordeaux, France
Lartigau, M., Ouattara, E. N., Tumiotto, C., Wodrich, H., Busson, L., Trimoulet, P., Thiel, E., Nouzille, M., Dubos, M., Lafon, M., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105134 · Cited by 2
Garnett, L., Tran, K. N., Chan, M., Tierney, K. J., Schiffman, Z., Audet, J., Lew, J. M., Meilleur, C. E., Chan, M., Manguiat, K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.16.496375 · Cited by 2
Impact of Prior Infection on Protection and Transmission of SARS-CoV-2 in Golden HamstersPreprint
Zhang, C., Guo, Z., Li, N., Cui, H. Y., Meng, K., Liu, L., Zhao, L., Zhang, S., Qin, C., Liu, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.30.428920 · Cited by 2
Yendewa, G. A., Olasehinde, T., Mulindwa, F., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf013 · Cited by 2
“Currently available SARS-CoV-2 vaccines have demonstrated efficacy in reducing disease severity, as well as hospitalization, ICU admission, and mortality rates in the general population [45–47].”
Adverse effects of COVID-19 vaccines in university students
Jongmekwamsuk, K., Hanvivattanakul, S., Vanichanan, J., & Khawcharoenporn, T. (2024) · F1000Research · doi:10.12688/f1000research.145862.1 · Cited by 1
Effect of mRNA COVID-19 vaccine on ovarian reserve of women of reproductive age
Kumbasar, S., Salman, S., Çakmak, G. N., Gencer, F. K., Sicakyüz, L. S., & Kumbasar, A. N. (2023) · Ginekologia Polska · doi:10.5603/gpl.94997 · Cited by 3
Navigating Coronavirus Disease 2019 in Immunocompromised Populations
Alsoubani, M., & Chow, J. K. L. (2025) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.02.005 · Cited by 2
Boon, A. C. M., Darling, T. L., Harastani, H., Joshi, A., Bricker, T. L., Seehra, K., Hassan, A. O., & Diamond, M. (2023) · Research Square · doi:10.21203/rs.3.rs-3185983/v1 · Cited by 2
Tamada, Y., Takeuchi, K., Kusama, T., Maeda, M., Murata, F., Osaka, K., & Fukuda, H. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.035 · Cited by 2
Engineered migrasomes provide a robust and thermally stable vaccination platformPreprint
Wang, D., Wang, H., Wan, W., et al. (2024) · eLife · doi:10.7554/elife.97621 · Cited by 2
“The huge success of mRNA vaccines in the fight against the Covid-19 pandemic further supports the importance of developing vaccine platforms based on different underlying biological mechanisms ( Park et al., 2021 ; Polack et al., 2020 ; Baden et al., 2021 ; Gui et al., 2023 ).”
Are some physicians afraid of the COVID-19 vaccines? A tale of motivated reasoning
Correia, L. C. L., & Segundo, J. D. D. B. (2021) · Journal of Evidence-Based Healthcare · doi:10.17267/2675-021xevidence.v2i2.3813 · Cited by 1
Wunderlich, B., Feijoo, B., Limaye, R. J., Moulton, L. H., & Talaat, K. R. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2521192 · Cited by 2
“…(a two-dose regimen, 21 days apart, of Pfizer-BioNTech showed 95% efficacy preventing COVID-19 illness whereas the AstraZeneca vaccine, given in two doses 28 days apart, conferred an efficacy of 74%), 8,26 participants still overwhelmingly were glad they joined and would have participated again.”
Yoshida, T., Takashima, K., Mtali, Y. S., Miyashita, Y., Iwamoto, A., Fukushima, Y., Nakamura, K., & Oshiumi, H. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkae049 · Cited by 3
Vaccination and Future of Coronavirus.
Moghadami, M., Amini, M., & Moghadami, M. (2022) · PubMed Central · doi:10.30476/ijms.2022.48591 · Cited by 2
Kwon, Y. S., Park, S. H., Kim, H. J., Park, J. S., Kim, M. A., Kim, T. H., Lee, J. Y., & Kim, J. Y. (2024) · Journal of Korean Medical Science · doi:10.3346/jkms.2024.39.e55 · Cited by 2
Knowledge, attitudes and perceptions of a patient population on the COVID-19 vaccine rollout
Purasram, M., Bangalee, V., Oosthuizen, F., & Moodley, R. (2022) · Health SA = SA Gesondheid · doi:10.4102/hsag.v27i0.1845 · Cited by 1
“These consisted of mandatory wearing of face coverings, hand hygiene, physical distancing, quarantining and lockdowns (Polack et al. 2020).”
BackgroundLuxi, N., Ciccimarra, F., Bellitto, C., Raethke, M., van Hunsel, F. P. A. M., Lieber, T., Mulder, E., L’Abbate, L., Marques, F. B., Furci, F., et al. (2024) · Vaccines · doi:10.3390/vaccines12091059 · Cited by 2
“In line with what was reported in the literature [20] and pivotal trials of COVID-19 vaccines in the general population [21–24], the most frequently reported ADRs in both cohorts were solicited ADRs, including injection site pain, headache, myalgia, and malaise, among the different doses.”
ResultStabilizing Prefusion SARS-CoV-2 Spike by Destabilizing the Postfusion Conformation
Chakraborty, D., Singh, R., Rajmani, R. S., Kumar, S., Ringe, R. P., & Varadarajan, R. (2025) · Vaccines · doi:10.3390/vaccines13030315 · Cited by 5
COVID-19 vaccine-related axillary edema in breast imaging setting
Freitas, V., Ghai, S., Au, F. W.-F., et al. (2021) · Radiology Case Reports · doi:10.1016/j.radcr.2021.11.075 · Cited by 2
“[9] Polack FP , Thomas SJ , Kichin N , et al.”
SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients
Geinitz, H., Silberberger, E., Spiegl, K. J., Feichtinger, J., Wagner, H., Hermann, P., Bräutigam, E., Track, C., Weis, E. M., Venhoda, C., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.006 · Cited by 2
Bethiana, T., Aljabbari, A., Li, Y., Mitra, H., Baghbanbashi, M., Harris, G., Dasaro, S. R., Masoomi, F., Vago, F. S., Hartzler, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.07.687311 · Cited by 2
Zhai, Y., Ku, M., Yang, K., Patil, A., Prabhala, P., He, L., Man, Y., Spörri, S. B., Gharpure, S., Isaacs, A. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.16.649172 · Cited by 2
“mRNA vaccines have been essential in controlling the COVID-19 pandemic 1,2 .”
de Oliveira, L. A. R., Correa, A. S., de Jesus, T. A., Bortolini, M. J. S., Taketomi, E. A., & Resende, R. (2024) · Vaccines · doi:10.3390/vaccines12040408 · Cited by 2
“In other studies, including phase II clinical trials, more than 80% of the participants also reported the same effect after vaccination [36,37].”
BackgroundHuang, M., Wang, C., Wang, X., Chen, D., Ling, J., Yu, Y., Zhang, M., Wang, Y., Xu, C., Shen, S., et al. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102943 · Cited by 3
Noé, A., & Ewer, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91146-7.00001-9 · Cited by 2
Konishi, A., Fukushima, W., Matsuura, T., Ohfuji, S., Kase, T., Kondo, K., Matsumoto, K., Suita, A., Mukai, E., Kasamatsu, A., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2518646 · Cited by 2
Çavuş, S. A., Çelik, M., Süner, A. F., Güzel, I., Irmak, Ç., Çağlayan, D., Öztürk, H. G., Şiyve, N., Appak, Ö., IŞIK, E., et al. (2023) · Immunology Letters · doi:10.1016/j.imlet.2023.08.002 · Cited by 3
A case for conducting business-to-business experiments with multi-arm multi-stage adaptive designs
Legare, J., Yao, P., & Lo, V. S. Y. (2022) · Journal of Marketing Analytics · doi:10.1057/s41270-022-00177-4 · Cited by 3
COVID-19 vaccine hesitancy in Australian patients with solid organ cancersPreprint
Bain, N. T., Nguyen, M., Grech, L., et al. (2022) · medRxiv · doi:10.1101/2022.07.08.22277398 · Cited by 2
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.